Caprico Biotechnologies

Executive Summary

Caprico Biotechnologies is a privately held US company that develops and manufactures recombinant antibodies and proteins for research and diagnostic applications. Founded in 2006 and headquartered in Norcross, Georgia, the company operates a cGMP/ISO-certified facility specializing in flow cytometry reagents, custom conjugation services, and antibody design. Its products support life sciences research, immunophenotyping, and diagnostic assay development, positioning it as a supplier to academic and biopharma customers. As a private entity, Caprico's financials and growth trajectory are not publicly disclosed, but its long-standing presence and certified facility indicate operational stability. However, the company faces competitive pressure from larger antibody manufacturers and contract research organizations. The lack of recent public announcements or disclosed pipeline suggests a steady-state business model focused on service and catalog sales rather than high-growth drug development. Overall, Caprico Biotechnologies occupies a niche but essential role in the reagent supply chain, with modest visibility and limited near-term catalysts.

Upcoming Catalysts (preview)

• Q4 2026Expansion of Recombinant Antibody Catalog70% success
• H1 2027Strategic Partnership with Diagnostic Developer60% success
• Q2 2026ISO Certification Renewal or Upgrade90% success